Longitudinal Analysis of Neutralizing Potency Against SARS-CoV-2 in the Recovered Patients After Treatment with or Without Favipiravir

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2022 Apr 23

PMID 35458400

Authors

Kanako Shinada

Takashi Sato

Saya Moriyama

Yu Adachi

Masahiro Shinoda

Shinichiro Ota

Miwa Morikawa

Masamichi Mineshita

Takayuki Matsumura

Yoshimasa Takahashi

Masaharu Shinkai

Affiliations

Soon will be listed here.

Abstract

The effect of treatment with favipiravir, an antiviral purine nucleoside analog, for coronavirus disease 2019 (COVID-19) on the production and duration of neutralizing antibodies for SARS-CoV-2 was explored. There were 17 age-, gender-, and body mass index-matched pairs of favipiravir treated versus control selected from a total of 99 patients recovered from moderate COVID-19. These subjects participated in the longitudinal (>6 months) analysis of (i) SARS-CoV-2 spike protein’s receptor-binding domain IgG, (ii) virus neutralization assay using authentic virus, and (iii) neutralization potency against original (WT) SARS-CoV-2 and cross-neutralization against B.1.351 (beta) variant carrying triple mutations of K417N, E484K, and N501Y. The results demonstrate that the use of favipiravir: (1) significantly accelerated the elimination of SARS-CoV-2 in the case vs. control groups (p = 0.027), (2) preserved the generation and persistence of neutralizing antibodies in the host, and (3) did not interfere the maturation of neutralizing potency of anti-SARS-CoV-2 and neutralizing breadth against SARS-CoV-2 variants. In conclusion, treatment of COVID-19 with favipiravir accelerates viral clearance and does not interfere the generation or maturation of neutralizing potency against both WT SARS-CoV-2 and its variants.

Citing Articles

Special Issue "SARS-CoV-2 Innate and Adaptive Immune Responses".

Planes R, Bahraoui E Viruses. 2022; 14(11).

PMID: 36366460 PMC: 9695004. DOI: 10.3390/v14112363.

Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study.

Sirijatuphat R, Manosuthi W, Niyomnaitham S, Owen A, Copeland K, Charoenpong L Emerg Microbes Infect. 2022; 11(1):2197-2206.

PMID: 35997325 PMC: 9518247. DOI: 10.1080/22221751.2022.2117092.

References

Gluck V, Grobecker S, Tydykov L, Salzberger B, Gluck T, Weidlich T . SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19. Infection. 2021; 49(4):739-746. PMC: 7944246. DOI: 10.1007/s15010-021-01598-6. View

Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R . The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021; 11(1):11022. PMC: 8155021. DOI: 10.1038/s41598-021-90551-6. View

Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J . Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021; 592(7854):438-443. DOI: 10.1038/s41586-021-03402-9. View

Alqahtani J, Oyelade T, Aldhahir A, Alghamdi S, Almehmadi M, Alqahtani A . Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. PLoS One. 2020; 15(5):e0233147. PMC: 7213702. DOI: 10.1371/journal.pone.0233147. View

Altay O, Mohammadi E, Lam S, Turkez H, Boren J, Nielsen J . Current Status of COVID-19 Therapies and Drug Repositioning Applications. iScience. 2020; 23(7):101303. PMC: 7305759. DOI: 10.1016/j.isci.2020.101303. View

Gottlieb R, Nirula A, Chen P, Boscia J, Heller B, Morris J . Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2021; 325(7):632-644. PMC: 7821080. DOI: 10.1001/jama.2021.0202. View

Bosnjak B, Stein S, Willenzon S, Cordes A, Puppe W, Bernhardt G . Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cell Mol Immunol. 2020; 18(4):936-944. PMC: 7604543. DOI: 10.1038/s41423-020-00573-9. View

Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi M, Khaloo V, Shahriarirad R . Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021; 21(1):337. PMC: 8035859. DOI: 10.1186/s12879-021-06045-3. View

Williamson E, Walker A, Bhaskaran K, Bacon S, Bates C, Morton C . Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584(7821):430-436. PMC: 7611074. DOI: 10.1038/s41586-020-2521-4. View

10.

Moriyama S, Adachi Y, Sato T, Tonouchi K, Sun L, Fukushi S . Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. Immunity. 2021; 54(8):1841-1852.e4. PMC: 8249673. DOI: 10.1016/j.immuni.2021.06.015. View

11.

Shinkai M, Tsushima K, Tanaka S, Hagiwara E, Tarumoto N, Kawada I . Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. Infect Dis Ther. 2021; 10(4):2489-2509. PMC: 8396144. DOI: 10.1007/s40121-021-00517-4. View

12.

Shinahara W, Takahashi E, Sawabuchi T, Arai M, Hirotsu N, Takasaki Y . Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis. PLoS One. 2013; 8(7):e70060. PMC: 3714257. DOI: 10.1371/journal.pone.0070060. View

13.

Takahashi E, Kataoka K, Fujii K, Chida J, Mizuno D, Fukui M . Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus. Microbes Infect. 2010; 12(10):778-83. DOI: 10.1016/j.micinf.2010.04.013. View

14.

Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S . SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat Commun. 2021; 12(1):1813. PMC: 7985370. DOI: 10.1038/s41467-021-22034-1. View

15.

Salton F, Confalonieri P, Meduri G, Santus P, Harari S, Scala R . Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia. Open Forum Infect Dis. 2020; 7(10):ofaa421. PMC: 7543560. DOI: 10.1093/ofid/ofaa421. View

16.

Volz E, Mishra S, Chand M, Barrett J, Johnson R, Geidelberg L . Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021; 593(7858):266-269. DOI: 10.1038/s41586-021-03470-x. View

17.

Marois I, Cloutier A, Garneau E, Lesur O, Richter M . The administration of oseltamivir results in reduced effector and memory CD8+ T cell responses to influenza and affects protective immunity. FASEB J. 2014; 29(3):973-87. DOI: 10.1096/fj.14-260687. View

18.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

19.

Udwadia Z, Singh P, Barkate H, Patil S, Rangwala S, Pendse A . Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2020; 103:62-71. PMC: 7668212. DOI: 10.1016/j.ijid.2020.11.142. View

20.

Garcia-Beltran W, Lam E, Astudillo M, Yang D, Miller T, Feldman J . COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021; 184(2):476-488.e11. PMC: 7837114. DOI: 10.1016/j.cell.2020.12.015. View